ArticleTumour virus research2026
HTLV-1 HBZ inhibits DHX9 to reprogram circRNA biogenesis in ATLL.
Article in Tumour virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human T-cell Leukemia Virus type 1 (HTLV-1) drives Adult T-cell Leukemia/Lymphoma (ATLL) through sustained expression of the viral oncoprotein HBZ. Although HBZ is known to reshape host transcriptional programs, its role in post-transcriptional regulation in ATLL remains poorly understood. Here, we uncover a mechanism by which HBZ reprograms circular RNA (circRNA) biogenesis to support leukemic cell survival. Comprehensive circRNA profiling across ATLL subtypes revealed extensive circRNA remodeling, with distinct signatures associated with aggressive ATLL subtypes. Among these, circAFF2(3) is markedly upregulated in aggressive ATLL, and functional analyses show that its expression enhances, whereas its silencing reduces, the survival of HTLV-1-transformed T cells. Mechanistically, we show that HBZ interacts with the RNA helicase DHX9 and inhibits its helicase activity at intronic double-stranded RNA structures flanking circularized exons. Using both endogenous and synthetic circRNAs, we demonstrate that this inhibition allows RNA duplexes to persist, thereby promoting back-splicing and the accumulation of DHX9-sensitive circRNAs, including circAFF2(3). Together, these findings reveal that HTLV-1 hijacks host RNA helicase activity to reprogram circRNA biogenesis, identifying the HBZ-DHX9 axis as a novel post-transcriptional mechanism contributing to ATLL development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.